Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients – underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn:
“In a multicenter observational study, 729 patients with metastatic castration-resistant prostate cancer (mCRPC) who participated in four previously completed prospective studies — PROCURE Biomarkers Platform: PROREPAIR-B (NCT03075735), PROSENZA (NCT02922218), PROSTAC (NCT02362620), and PROSABI (NCT02787837) were included.
BRCA1/2 mutations were detected in 96 patients (74% – somatic mutations, 26% – germinal), while other mutations (non-BRCA1/2 homologous recombination deficiency – non-BRCA-HRD) were present in 127 patients, and no HRD in 506 patients. All patients were treated with study-defined first-line treatments (abiraterone acetate, enzalutamide, docetaxel, or cabazitaxel).
The analysis demonstrated that mCRPC patients with BRCA1/2 mutations had significantly worse outcomes in terms of radiographic progression-free survival (rPFS), second progression-free survival (PFS2), and overall survival (OS) compared to other mCRPC patient groups (non-BRCA-HRD and no HRD).
The median outcomes were significantly poorer in the BRCA1/2-mutated patients compared to patients without BRCA1/2 mutations:
-
- rPFS – 7.1 months v.10.3 months (HR for rPFS=1.7; 95%CI 1.32-2.19)
- PFS2 – 12.6 months v. 15.9 months (HR for PFS2=1.81; 95%CI 1.44-2.27)
- OS – 19.4 months v. 27.9 months (HR for OS=1.95; 95%CI 1.55-2.45)
The results of this analysis provide critical data suggesting the need for early assessment of BRCA1/2 status in prostate cancer patients demonstrating early signs of castration resistance to guide the first-line treatment of mCRPC optimally.
The availability of PARPi (olaparib) and abiraterone combination in the first-line treatment of mCRCP patients has dramatically changed the initial treatment strategy in this population. Olaparib and abiraterone combination has significantly improved the overall survival of BRCA1/2-mutated mCRCP patients (PROPEL study), thus transforming the poor prognostic factor into a crucial, positive predictive factor.”
Read further.
Source: Piotr Wysocki/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time, it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023